{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:00Z","timestamp":1788243360165,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T00:00:00Z","timestamp":1330387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To evaluate the long\u2010term (up to 5\u2003years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial\u2010onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open\u2010label extension trial SP756 (NCT00522275).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Patients who completed the double\u2010blind trial SP754 (NCT00136019) were eligible to participate in this open\u2010label extension trial (SP756). At the conclusion of trial SP754, patients had transitioned to lacosamide 200\u2003mg\/day. Subsequent dosage adjustments of lacosamide (100\u2013800\u2003mg\/day) and\/or concomitant AEDs were allowed to optimize tolerability and seizure reduction. Treatment\u2010emergent adverse events (TEAEs), vital signs, body weight, clinical laboratory data, electrocardiography studies, and seizure frequency were evaluated.<\/jats:p><jats:p><jats:bold>Key Findings:\u2002<\/jats:bold> A total of 308 patients received open\u2010label lacosamide and 138 patients (44.8%) completed the long\u2010term trial. The median modal dose (defined as the daily lacosamide dose a patient received for the longest duration during the treatment period) was 500\u2003mg\/day. The percentages of patients with lacosamide exposure &gt;1, &gt;2, &gt;3, or &gt;4\u2003years were 75%, 63%, 54%, and 29%, respectively. Primary reasons for discontinuation were lack of efficacy (26%) and adverse events (11%). Common TEAEs (\u226515%) were dizziness, headache, contusion, nausea, convulsion, nasopharyngitis, fall, vomiting, and diplopia. TEAEs that led to discontinuation in \u22651.0% of patients were dizziness (1.6%) and convulsion (1.0%). The median percent reductions from baseline of trial SP754 in 28\u2010day seizure frequency were 53.4%, 55.2%, 58.1%, and 62.5%, respectively, for 1\u2010, 2\u2010, 3\u2010, and 4\u2010year completers. The \u226550% responder rates were 52.8%, 56.5%, 58.7%, and 62.5% for 1\u2010, 2\u2010, 3\u2010, and 4\u2010year completers, respectively. Seven of eight patients on lacosamide monotherapy for \u226512\u2003months were deemed 50% responders. Of patients exposed to lacosamide \u22652\u2003years, 3.1% remained seizure\u2010free for a period \u22652\u2003years.<\/jats:p><jats:p><jats:bold>Significance:\u2002<\/jats:bold> Long\u2010term (up to 5\u2003years) lacosamide treatment was generally well tolerated. The safety profile of lacosamide observed in this trial is consistent with that established in previous double\u2010blind, placebo\u2010controlled trials. Although the open\u2010label trial design limits the analysis of efficacy, long\u2010term reduction in seizure frequency and maintenance of efficacy was observed.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2012.03407.x","type":"journal-article","created":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T16:48:21Z","timestamp":1330447701000},"page":"521-528","source":"Crossref","is-referenced-by-count":77,"title":["Long\u2010term safety and efficacy in patients with uncontrolled partial\u2010onset seizures treated with adjunctive lacosamide: Results from a phase III open\u2010label extension trial"],"prefix":"10.1111","volume":"53","author":[{"given":"Aatif","family":"Husain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Faught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Isojarvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"McShea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01188.x"},{"issue":"4","key":"e_1_2_7_3_1","article-title":"Safety and tolerability of lacosamide: a summary of adverse events in epilepsy clinical trials. European Congress on Epileptology \u2013 8th","volume":"50","author":"Biton V","year":"2009","journal-title":"Epilepsia"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.10.004"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2009.07.005"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02177.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586830-000000000-00000"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02496.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.1999.0348"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01951.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.08.001"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S4063"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2012.03407.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2012.03407.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T19:33:08Z","timestamp":1698694388000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2012.03407.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1111\/j.1528-1167.2012.03407.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03407.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]}}}